Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV003476420 | SCV004199806 | uncertain significance | Neuroblastoma, susceptibility to, 3 | 2023-08-21 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004634267 | SCV005121270 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-03-27 | criteria provided, single submitter | clinical testing | The p.P1094L variant (also known as c.3281C>T), located in coding exon 20 of the ALK gene, results from a C to T substitution at nucleotide position 3281. The proline at codon 1094 is replaced by leucine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this alteration remains unclear. |